Mersana Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Mersana Therapeutics

08/08/2023 14:36

* Mersana Therapeutics Inc  MRSN.OQ  reported a quarterly
adjusted
loss of 47 cents​​ per share for the quarter ended in June. The
mean expectation of nine analysts for the quarter was for a loss
of 44 cents per share.
    * Revenue rose 148.7% to $10.65 million from a year ago;
analysts
expected $12.95 million. 
    * Mersana Therapeutics Inc's reported EPS for the quarter
was a
loss of 47 cents​.
    * The mean earnings estimate of analysts had risen by
about 11.1%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates 
    * Mersana Therapeutics Inc shares had fallen by 63.5% this
quarter and lost 79.5% so far this year.
    * The company reported a quarterly loss of $54.31 million.
    * Wall Street's median 12-month price target for Mersana
Therapeutics Inc is $1.50 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 6
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 8 at 01:36 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.44          -0.47          Missed
 Mar. 31 2023      -0.44          -0.52          Missed
 Dec. 31 2022      -0.50          -0.44          Beat
 Sep. 30 2022      -0.09          -0.61          Missed